Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Trinity Biotech, a provider of diagnostic products for the point-of-care and clinical laboratory markets, has launched its new HIV incidence assay.
Subscribe to our email newsletter
Trinity Biotech’s HIV-1 Bed incidence assay is a second generation assay designed to detect recent HIV seroconversion by determination of the relative proportion of HIV specific IgG to total IgG.
The HIV incidence assay is used for surveillance purposes by health agencies on a global basis to assist, monitor, and evaluate HIV prevention programs; to help plan vaccine trials; to identify high risk populations; and to target resources used in the fight against HIV. It is a vital tool in determining the spread of the disease.
The test was developed by the US Centers for Disease Control and Prevention (CDC). The test will be manufactured by Trinity, which includes Trinity developed key reagent ‘Bed peptide’, at its facility in Carlsbad, California, under a licensing agreement with CDC.
Brendan Farrell, CEO of Trinity Biotech, said: “We are delighted to offer this new HIV incidence assay and believe it will serve as an invaluable tool to global health agencies tracking the spread of the disease.”